With Pfizer's (PFE 0.23%) third-quarter results set to be released in late October, the best way for investors to prepare for the report is to review last quarter's results. The following video focuses on the Q2 results from the big pharma's oncology division. This division contributed only 3% to the company's top line, but sales grew 24% in the second quarter, and the company is developing a new cancer drug, palbociclib, which received the FDA's breakthrough designation this year. This is a competitive designation that other drug developers, such as Pharmacyclics (NASDAQ: PCYC) and its partner Johnson & Johnson (JNJ 0.29%), have also benefited from. Analysts David Williamson and Max Macaluso discuss these therapeutics in the following video.
